jing

In the NewsChengdu, China, September 9, 2021Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid cancer cells for disruption”, which was issued …

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Read More »

In the NewsChengdu, China, 14 July 2021Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today appointment of Dr. Hong Liu as VP of Clinical Development. A physician-scientist, he will be based in Chengdu and …

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Read More »

In the NewsMay 11, 2021Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer Unique target for MYC-SL compounds identified for precision oncology Three classes of novel synthetic lethal compounds (MYC-SL) identified against this target, acting through interfering mitosis and blocking cytokinesis Therapeutic efficacy demonstrated in a large panel …

Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer Read More »

In the NewsFebruary 8, 2021Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline Chengdu, China, 8 February 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m), it has already achieved positive …

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline Read More »

In the NewsJanuary 12, 2021Anticancer Bioscience Presenting at Biotech Showcase™ Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time Chengdu, China, 12 January 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it is participating in Biotech Showcase™ Digital 2021, for the first time, providing …

Anticancer Bioscience Presenting at Biotech Showcase™ Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time Read More »